Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study

Nanobiotix (NBTX) shares were up around 13% during the pre-market hours on Tuesday after the company announced that it has initiated dosing in a mid-stage study evaluating a potential first-in-class radioenhancer, JNJ-1900 (NBTXR3), to treat lung cancer patients. The candidate was added to Nanobiotix’s pipeline following a licensing deal for the global co-development and commercialization with pharma bigwig, Johnson & Johnson (JNJ) , in 2023.The company stated that it has dosed the first patient with JNJ-19 ...